Raymond James Downgrades Verastem (VSTM) to Outperform

JMP Securities Downgrades Verastem (VSTM) to Market Perform

JMP Securities downgraded Verastem (NASDAQ: VSTM) from Market Outperform to Market Perform.

For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.

Shares of Verastem closed at $1.85 yesterday.

Jefferies Downgrades Verastem (VSTM) to Hold

Jefferies downgraded Verastem (NASDAQ: VSTM) from Buy to Hold with a price target of $2.00 (from $18.00).

For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.

Shares of Verastem closed at $5.67 yesterday.

UBS Downgrades Verastem (VSTM) to Neutral

UBS downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00.

For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.

Shares of Verastem closed at $5.67 yesterday.

Mizuho Securities Downgrades Verastem (VSTM) to Neutral

Mizuho Securities downgraded Verastem (NASDAQ: VSTM) from Outperform to Neutral with a price target of $2.00 (from $21.00).

Analyst Eric Criscuolo commented, "We are downgrading VSTM from Buy to Neutral and lowering our PT from $21 to $2 following the failure of the COMMAND trial of... More

Roth Capital Downgrades Verastem (VSTM) to Neutral

Roth Capital downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00 (from $23.00).

Analyst Joseph Pantginis commented, "There has been a major disappointment this morning as the pivotal COMMAND study using VS-6063 in mesothelioma was halted for futility following the... More

Verastem (VSTM) Ceases VS-6063 Phase 2 Enrollment in Mesothelioma Following DSMB Recommendation

Verastem (NASDAQ: VSTM) announced that the Company has stopped enrollment in the Phase 2 registration-directed, double-blind, placebo-controlled study (COMMAND) of VS-6063 for patients with mesothelioma. The decision to stop enrollment for futility followed a Data Safety Monitoring Board (DSMB) review of a pre-planned interim analysis. The results of the analysis demonstrated that VS-6063 had a generally well... More